Use this button to switch between dark and light mode.

Ibogaine Drawing Attention from State Lawmakers and Trump & More

April 22, 2026 (1 min read)

State and Federal Funding Flowing for Ibogaine Research

President Donald Trump signed an executive order providing up to $50 million in federal funding for states to conduct research on ibogaine, a psychedelic drug that hasn’t received FDA approval for any medical use but has shown promise for treating opioid use disorder and PTSD. Several states, including Arizona, Mississippi and Texas have already approved funding for clinical trials on the drug, and ibogaine bills are also advancing in Georgia, Louisiana, Maryland, New Hampshire, Oklahoma and Tennessee. (PLURIBUS NEWS)

State AGs Pushing for Federal Drug Pricing Transparency Rules

A bipartisan group of attorneys general led by Oklahoma AG Gentner Drummond (R) is calling for new federal rules to increase prescription drug pricing transparency. The AGs want the U.S. Department of Labor to require pharmacy benefit managers to report revenue details twice a year. They also want to make sure the new rules don’t override existing state laws and that federal regulators coordinate their enforcement efforts with state attorneys general. (MCCARVILLE REPORT)

—Compiled by SNCJ Managing Editor KOREY CLARK

Visit our webpage to connect with a LexisNexis® State Net® representative and learn how the State Net legislative and regulatory tracking service can help you identify, track, analyze and report on relevant legislative and regulatory developments.

Subscribe

News & Views from the 50 States

Free subscription to the Capitol Journal keeps you current on legislative and regulatory news.